文献速递肿瘤 PET/CT核素与放射性配体治疗

[68Ga]Ga-DATA-TOC用于神经内分泌肿瘤显像:与[68Ga]Ga-DOTA-NOC PET/CT的比较

Evaluation of [68Ga]Ga-DATA-TOC for imaging of neuroendocrine tumours: comparison with [68Ga]Ga-DOTA-NOC PET/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-11-22

视觉评估显示两者生物分布与图像质量相似,患者-wise分析中两种示踪剂均检出44例(88%)阳性。基于病灶分析,[68Ga]Ga-DATA-TOC与[68Ga]Ga-DOTA-NOC的符合率为98.6%(235个病灶中232个一致)。

要点

  • [68Ga]Ga-DATA-TOC与[68Ga]Ga-DOTA-NOC视觉图像质量及生物分布相似。
  • 患者-wise分析两者均检出44例(88%)阳性,6例(12%)阴性。
  • 病灶-wise分析两者符合率98.6%(232/235个病灶)。

核心结论

  • [68Ga]Ga-DATA-TOC PET/CT显像结果与[68Ga]Ga-DOTA-NOC相当,有望成为有效且安全的替代选择,并具有即时药盒式合成简便、成本效益高和产率高的优势。

主要发现

  • 视觉评估显示[68Ga]Ga-DATA-TOC的生物分布和图像质量与[68Ga]Ga-DOTA-NOC相似。
  • [68Ga]Ga-DATA-TOC的生理性肝脏摄取低于[68Ga]Ga-DOTA-NOC(7.65 ± 5.37 vs 8.94 ± 5.95,p = 0.009)。
  • 患者-wise分析中,两种示踪剂均检出44例(88%)阳性、6例(12%)阴性。
  • 病灶-wise分析中,[68Ga]Ga-DATA-TOC与[68Ga]Ga-DOTA-NOC的符合率为98.6%(235个病灶中检出232个一致)。
  • 肿瘤靶病灶SUVmax在两种示踪剂间无显著差异(36.63 ± 32.24 vs 40.82 ± 36.89,p = 0.097),肿瘤/肝脏SUVmax比值亦无显著差异(5.99 ± 5.52 vs 5.67 ± 4.96,p = 0.77)。

关键数值与推荐

  • 视觉评估比较生物分布与图像质量;半定量比较肿瘤、纵隔和肝脏的SUVmax及肿瘤/肝脏(T/L)、肿瘤/纵隔(T/M)SUVmax比值。
  • 采用非参数相关样本Wilcoxon符号秩检验比较SUVmax值及比值。
  • 患者-wise及病灶-wise分析用于比较。

临床怎么用

  • [68Ga]Ga-DATA-TOC可作为[68Ga]Ga-DOTA-NOC的替代示踪剂用于GEP-NET的PET/CT显像,且具有室温标记、即时药盒式合成简便、成本效益高和产率高的优势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Recently, the new hybrid chelator DATA (6-amino-1,4-diazepine-triacetate) has been introduced, which has the advantage of high yield and radiolabelling of DATA-based octreotide derivative (TOC) at room temperature in contrast to tetraazacyclododecane-1,4,7,10-tetraacetate (DOTA) that needs 95 °C for effective labelling. However, the diagnostic potential of DATA-TOC has not been studied with other chelators in humans. The aim of this study was to compare the diagnostic efficacy of [68Ga]Ga-DATA-TOC with [68Ga]Ga-DOTA-NOC (which is the current standard for imaging neuroendocrine tumours (NET)) in patients of gastroenteropancreatic neuroendocrine tumours (GEP-NETs). METHODS: Fifty patients (thirty-one males and nineteen females) with biopsy-proven GEP-NETs were included in the study. Patients age ranged from 14 to 75 years (mean 46.11 years). All patients underwent two PET studies with [68Ga]Ga-DATA-TOC and [68Ga]Ga-DOTA-NOC. Images were evaluated visually and semi-quantitatively using maximum standardized uptake values (SUVmax) of tumour, mediastinum and liver. Tumour-to-liver (T/L) and tumour-to-mediastinum (T/M) SUVmax ratios were computed. For the purpose of comparison, patient-wise as well as lesion-wise analysis was carried out. The nonparametric-related samples Wilcoxon signed-rank test was used for comparison of the SUVmax values and ratios. RESULTS: On visual evaluation, the biodistribution and image quality of [68Ga]Ga-DATA-TOC was similar to [68Ga]Ga-DOTA-NOC. Physiological liver uptake was lower in [68Ga]Ga-DATA-TOC as compared with [68Ga]Ga-DOTA-NOC, 7.65 ± 5.37 vs 8.94 ± 5.95 (p = 0.009), respectively. On a patient-wise analysis, both [68Ga]Ga-DATA-TOC and [68Ga]Ga-DOTA-NOC were lesion-positive in the 44 patients (88%) and were negative in the 6 patients (12%). On a lesion-based analysis, [68Ga]Ga-DATA-TOC had 98.6% concordance with [68Ga]Ga-DOTA-NOC (232 out of 235 lesions detected). The target tumour SUVmax on [68Ga]Ga-DATA-TOC and [68Ga]Ga-DOTA-NOC were 36.63 ± 32.24 and 40.82 ± 36.89, respectively (p = 0.097). The T/L SUVmax ratios were not significantly different (5.99 ± 5.52 vs 5.67 ± 4.96, p = 0.77). CONCLUSION: [68Ga]Ga-DATA-TOC PET/CT imaging produced results that were comparable with [68Ga]Ga-DOTA-NOC. It, thus, has potential utility as an effective and safe alternative to 68Ga-DOTA-NOC with the added benefit of ease, cost-effective and improved yield of instant kit-type synthesis.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Yadav D, Ballal S, Yadav MP, et al. Evaluation of [68Ga]Ga-DATA-TOC for imaging of neuroendocrine tumours: comparison with [68Ga]Ga-DOTA-NOC PET/CT. Eur J Nucl Med Mol Imaging. 2019. PMID: 31754796. doi:10.1007/s00259-019-04611-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。